Natco Pharma gets tentative approval for Yondelis generic

18 Aug 2022 , 08:38 AM

The US Food and Drug Administration has granted tentative approval to Natco Pharmas Abbreviated New Drug Application (ANDA) for trabectedin for injection (generic for Yondelis) for the 1mg/vial presentation. According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market. Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). It markets and distributes products in over 40 countries. On a consolidated basis, net profit of Natco Pharma rose 327.20% to Rs 320.40 crore on 115.60% increase in net sales to Rs 884.60 crore in Q1 June 2022 over Q1 June 2021. Shares of Natco Pharma fell 0.57% to Rs 651.30 on Wednesday, 17 August 2022. Powered by Capital Market – Live News